A Randomised, Double-blind, Placebo- and Active Comparator-controlled, Five Parallel Groups Study to Investigate the Efficacy and Safety of BI 44370 TA (50 mg, 200 mg, and 400 mg) Administered Orally Once During an Acute Migraine Attack of Moderate or Severe Intensity

Trial Profile

A Randomised, Double-blind, Placebo- and Active Comparator-controlled, Five Parallel Groups Study to Investigate the Efficacy and Safety of BI 44370 TA (50 mg, 200 mg, and 400 mg) Administered Orally Once During an Acute Migraine Attack of Moderate or Severe Intensity

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Dec 2014

At a glance

  • Drugs BI 44370; Eletriptan
  • Indications Migraine
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Oct 2012 Planned number of patients changed from 410 to 460 as reported by European Clinical Trials Database record.
    • 03 Jul 2012 Official title amended as reported by European Clinical Trials Database record.
    • 01 Jul 2009 Actual patient number (416) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top